Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

Description

This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.

Conditions

Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

Condition
Central Nervous System Lymphoma
Intervention / Treatment

-

Contacts and Locations

Columbus

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States, 43210

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * \* Adult (age ≥ 18 years at diagnosis)
  • * Diagnosis of DLBCL or PCNSL
  • * Planned to undergo treatment with HDMTX (≥ 3 g/m\^2) at the James Cancer Hospital.
  • * Ability to provide informed consent.
  • * \* Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation
  • * Pregnancy (positive serum or urine pregnancy test), lactating or breast feeding
  • * Prisoners or incarcerated patients
  • * Total bilirubin \> 5 mg/dL

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Ohio State University Comprehensive Cancer Center,

Timothy Voorhees, MD, PRINCIPAL_INVESTIGATOR, Ohio State University Comprehensive Cancer Center

Study Record Dates

2024-12-31